British drugmaker GSK has agreed to pay up to $2.2 billion to settle 80,000 US cases linking cancer to Zantac. GSK denies liability but aims to resolve the litigation, benefiting shareholders and removing financial uncertainty.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing